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Dr Anthony P. Furnary (Portland, Ore). Dr McDonnell, thank
you for a beautiful and very concise presentation. We can all be
frustrated by this SCIP measure. I think all in this room can agree
that the SCIP benchmarks that have been put forth are really scien-
tifically unfounded, and, as you have said, inaccurate. To me, they
make little sense. As you have shown, being an outlier at 6:00 AM
on the first or second day really has nothing at all to do with the
glycemic state of the patient in the first 3 days.
Just as the SCIP glycemic benchmarks have nothing to do with
glycemic state, I think it is important to note that tight glycemic
control has nothing to dowith cardiac surgery outcomes in patients
who do not have diabetes. This is a really important point. I want to
repeat it. There has not been a single study showing that tight gly-
cemic control alters cardiac surgery outcomes in patients who do
not have diabetes. The only outcomes benefits that have ever
been shown are in patients who have diabetes or in surgery patients
who are receiving total parenteral nutrition for more than 5 days.
A lot of authors have missed that important caveat. It is impor-
tant because it comes as no surprise, then, that any study that com-
bines both patients with diabetes and those without diabetes in its
study population and looks at glycemia-related outcome end
points will find that those glycemia-related outcomes are preor-
dained to be what everybody now calls ‘‘noninferior.’’ Thus it
does not matter whether you look at target blood glucose level,
moderate versus tight glucose control, or a glycemic SCIPmeasure
or you look at actual achieved 3BG; you will always end up with
a noninferior outcome.
Furthermore, in patients with diabetes, the achieved blood glu-
cose levels are always either at the upper end of the target blood
glucose range or, more frequently above that target range. If you
wanted to get 100% compliance within a target, say you wanted
to be 100% less than 180 mg/dL, then you would have to target
150 mg/dL to get everybody there, to less than 180 mg/dL. I
have 3 questions.
First, did you get a chance to analyze the outcomes of just your
diabetes subset of patients with regard to 3BG and SCIP
compliance?
Dr McDonnell. Thank you very much, Dr Furnary, for that ex-
cellent summary. I agree with the majority of your points. You are
absolutely right that the majority of the available prospective data
in group of patients who are newly revascularized supports the
concept that glycemic control reduces the excess risk seen in pa-
tients with diabetes having CABG surgery. Not all data are consis-
tent with this benefit being unique to patients with diabetes,
however, and subgroup analyses of larger studies suggest CABG
patients without diabetes may benefit substantially from postoper-
ative intensive insulin therapy.
I did look at the diabetes CABG subset. This represented 28% of
the entire cohort, so it was a small subset. Just of note, 75% of the
operations in this data set were CABG and 37% of the total group
had a prior diagnosis of diabetes.
We found that 3BG was almost the same between the patients
with diabetes and those without diabetes, 148 mg/dL versus 135
mg/dL, respectively, reflecting that all patients receive the same
glycemic care perioperatively. We did not see a difference in out-
comes between these groups, presumably for 2 reasons: (1) the
glucose difference was minimal; (2) the event rate was low, asThe Journal of Thoracic and Cawould be expected in a group of this size in many centers. Our pre-
vious speaker noted that the mortality reduction seen over the past
10 or 15 years in cardiac surgery is profound depending on the data
set you look at, and it is now difficult to show a difference in out-
comes owing to any single intervention, certainly in mortality.
Dr Furnary.As you know, we have developed the 3BG because
it covers every component of glycemia-related risk throughout the
postoperative period. SCIP decided not to use 3BG or not to use
any composite outcome for several reasons: (1) a composite out-
come is difficult to collect; (2) it is complex to collect; and (3) it
is costly to collect. What would your recommendation be to
SCIP? Furthermore, what is your recommendation for the STS
in regard to glycemic metrics for patients having cardiac surgery?
It is my opinion that the STS really ought to be in charge of this and
define a glycemia-related metric for all patients requiring cardiac
surgery—and use one that makes scientific sense. What should we
collect in the STS database and what should we tell SCIP that they
ought to collect for some sensible scientifically related composite
glucose measurement?
Dr McDonnell. Thank you for your question. First of all, I am
pleased to be part of this conversation, because I think that it is not
an easy answer and we need to discuss it across all involved disci-
plines. I would be happy, as would many of my colleagues, with
a measurement that involved more than 1 or 2 measurements to ar-
rive at a true mean and specifically avoid isolated measurements,
which are not valid as tools to assess overall glycemic control.
As an endocrinologist, I find it concerning that we are using iso-
lated measurements to judge the glycemic care of our patients hav-
ing cardiothoracic surgery. SCIP could potentially calculate 3BG
on a subset of patients randomly selected and report that in the
form of an audit, or we could collect 4 to 8 measurements over
the course of 2 to 3 days. The SCIP monitors may have difficulty
with these more complex measures inasmuch as it would increase
time required to collect data, and that would come at a cost. How-
ever, the conversation needs to continue, and, I agree, STS needs to
be in the forefront.
Dr Furnary. Last question:We know that 75% of the SCIP ‘‘vi-
olations’’ (I call them violations) were caused by a delayed start,
poor transition from intravenous to subcutaneous, or some other
protocol violation, and the remaining ones were caused just be-
cause they were on the protocol and were in that group of patients
who end up higher than the protocol target. We also know that the
actual achieved glucose is often higher than the target. Shouldn’t
we therefore just all lower our upper target range and to say 150
mg/dL and keep all our patients on insulin drip protocols for 3
days instead of just 18 hours? That way, all of the glycemia-related
risks are fully covered. This is what we have done in Portland, and
we end up having 100% SCIP compliance on this glycemic mea-
sure, so it is not so frustrating anymore. We just forget about the
SCIP thing, because it always works.
Dr McDonnell. I will be frank that it took us time, but we have
found that many of the elements related to SCIP failure that I noted
are remediable. We have remediated many of them in the past 1 to
2 years so that we are at 100% compliance for most months over
the past year. We have been over 95% for 2 years. The goal can
be reached in most patients inasmuch as insulin is certainly effec-
tive. However, reaching the SCIP goal, as we have shown, does not
have significant meaning for the patients. Of importance here isrdiovascular Surgery c Volume 145, Number 2 595
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not merely an attempt to arrive temporarily at the 6:00 AM target of
less than 200 mg/dL, after which control may be abandoned.
What I would also say is that intravenous insulin therapy that is
prolonged after cardiothoracic surgery with subcutaneous insulin
to cover meals is very elegant and is a beautiful therapy. However,
I just do not think it is available to every institution. For many rea-
sons, we decided to master the subcutaneous transition by day 2,
and that involved a team of providers, including me and another
attending, with fellows, pharmacists sometimes, and also midlevel
providers, who can be specifically trained to manage intensive sub-
cutaneous insulin in patients having cardiothoracic surgery.
I would say either way it is accomplishable, and whether you
are doing a prolonged insulin infusion on the step-down unit or
early transition to scheduled subcutaneous insulin, an enormous
amount of commitment to both the nurses and to patients is
required, and you know that better than anyone else.
Dr Lars G. Svensson (Cleveland, Ohio). Dr McDonnell, con-
gratulations on a very important and timely study. Unfortunately,
this is something that we are going to have to deal with increas-
ingly, as you, I am sure, are all too aware. At the moment, there
are some 70 patient and outpatient measures that are imposed on
institutions, and at the last count I saw, they are going up to about
120. Increasingly, we are going to be playing defense against all
these various quality measures, and it certainly is a challenge for
those that have to deal with responding to this and observing the
quality of our departments.
As you know, the bump-up in sugar after surgery is a normal re-
sponse to trauma.We all learned that in physiology, and our trauma
surgery colleagues have had to deal with the same issue. Unfortu-
nately, getting the SCIP measures changed has been very difficult.
As you know, the time interval, which is now measured, will be
changing. Fortunately, for those of you who had to deal with the
issue of cold patients in the ICU, we managed to convince various
people that the SCIP measure for that was completely wrong, that
we would be doing patients harm if we rewarm them after surgery
to the point that they are normothermic with the pump. So they did
respond to that.
In response to the issue of blood sugars, we went through vari-
ous changes to try to deal with this issue. We noticed that blood
sugar levels rose in patients who received vancomycin with a glu-
cose carrier; patients who were sicker, who usually went up to the
ICU late in the day or were on epinephrine and also had an increase
in their blood sugar levels. So we recommended various things,
and our nurses were very helpful. For example, a 10 o’clock
glucose value that rises above 160 mg/dL we recheck at 3 o’clock
to try to meet this very measure. The danger in this measure
aggressively is particularly that the patients could become
hypoglycemic.
I have a couple of questions. The categories of complications
that you looked at were fairly broad. The ones as a surgeon I would
worry about as potentially being a factor with high sugars and di-
abetes is in the patients with bilateral internal thoracic arteries and
the risk of wound infection. We know they have a higher risk. Do
you have the numbers to look at that subcategory of patients? Your
incidence of multiple organ failure was remarkably good and low,
but that may be another place where high sugars may play a role as
also with lactic acidosis. Did you look at these subgroups?596 The Journal of Thoracic and Cardiovascular SurgMy final question concerns talk about a National Institutes of
Health study within the cardiothoracic cooperative network look-
ing at this very issue. Is this something that you think should be
taken further?
Dr McDonnell. Thank you very much. I echo your sentiment
and your comments about the strategies that you have used to im-
prove or to reach the SCIP measure and your concern for the po-
tential to go overboard with targeted insulin therapy to attain
a glucose goal, placing patients at risk.
To answer your first question, we do not have the graft type in
this data set, specifically the bilateral internal thoracic arteries,
but we have discussed this as a variable that may be significant.
Your second question concerned the fact that SCIP is linked to
monetary reimbursement and to judging providers and their care.
I think it should go to wherever committee or organization it could
go to in order to make rationale change. Larger multi-institutional
studies are costly, but if they can be used to assess the relevance of
several SCIP measures, it may be of value. In my experience and
opinion, once a program has made the effort to control glucose
and if this can be proven or established by the institution, it is frus-
trating to have to address the randommiss, the randomSCIP outlier
who is not at increased risk of poor outcomes. Unfortunately, at our
institution we continue to have to respond to SCIP reviewers by
spending up to an hour per case trying to determine and document
why a patient had a glucose elevation for a few hours of their entire
stay, which likely has no relevance to their care. Additionally, we
are asked how to prevent this from happening, which, as we have
shown, is impossible to say for all patients inasmuch as in at least
25% of cases there is no identifiable reason for the hyperglycemic
event. This is consistent with the idea that transient physiologic hy-
perglycemia can be unpredictable after cardiothoracic surgery sur-
gery, which, despite having little to no clinical consequence,
currently has significant administrative consequence.
Dr Thomas M. Beaver (Gainesville, Fla). I would caution
against totally throwing SCIP out. I believe there is a ‘‘culture ef-
fect’’ in trying to make things better. I would also remind the audi-
ence that glucose is just one of the many SCIP measures, including
getting the antibiotics in on time during the time out with the anes-
thesiologist; stopping the antibiotics; appropriate choice of antibi-
otics; and warming patients. You can also look at the SCIP overall
composite score.Whatwe found at our own institution is that, aswe
have improved our SCIP composite score, our rate of global class I
surgical infections have decreased by 50% across the board.
Have you had a chance to look at your SCIP composite score in
this group of patients to determine whether that may have had any
effect?
Dr McDonnell. Thank you for your comment. I think that is
such an important way to end this session. SCIP is important in
the way it improved glycemic control and other evidence-based
practice in many institutions. Institutions should be held account-
able for their practice of evidence-based care, and this is
unquestionable for the sustained achievement of optimal patient
outcomes. The priority with SCIP continues to be in line with cli-
nicians, which is to optimize clinical outcomes.Whatwe and others
have tried to highlight, however, is that the parameters selected
have to be simple to measure as well as evidence-based and at min-
imum reflective of the actual practice. Otherwise, the SCIP culture
becomes a negative force as an unintended consequence.ery c February 2013
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knows the answer to this. I do not know whether the composite
score for cardiothoracic surgery has been linked to outcomes in
our institution. I do know that we have extremely low infection
rates, as many hospitals do now, after the institution of manyThe Journal of Thoracic and CaSCIP measures, not just glucose control. But I do not know
whether Dr Lazar wants to comment on that.
Dr Lazar. In brief, the answer is no, we have never ever been
able to correlate any of the SCIP measures with infection in our
institution.rdiovascular Surgery c Volume 145, Number 2 597
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